Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival

Yuan, Chen; Qian, Zhi Rong; Babić, Ana; Morales-Oyarvide, Vicente; Rubinson, Douglas A.; Kraft, Peter; Ng, Kimmie; Bao, Ying; Giovannucci, Edward; Ogino, Shuji; Stampfer, Meir J.; Gaziano, J. Michael; Sesso, Howard D.; Buring, Julie E.; Cochrane, Barbara B.; Chlebowski, Rowan T.; Snetselaar, Linda; Manson, JoAnn E.; Fuchs, Charles S.; Wolpin, Brian M.

doi:10.1200/jco.2015.66.3005

Cited by 47 publications

(51 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining 218 studies were evaluated based on full-text review, and 206 studies were excluded based on eligible criteria. Finally, twelve studies were included (Figure 1 ) [ 17 – 28 ].…”

Section: Resultsmentioning

confidence: 99%

Plasma 25-hydroxyvitamin D levels, vitamin D intake, and pancreatic cancer risk or mortality: a meta-analysis

et al. 2017

View full text Add to dashboard Cite

BackgroundThe associations between vitamin D status, including plasma 25-hydroxyvitamin D [25(OH)D] levels and vitamin D intake, and pancreatic cancer risk and mortality are inconsistent. The aims of this study are to evaluate the antitumor and therapeutic effects of vitamin D status for pancreatic cancer patients.MethodsA literature search for relevant studies was conducted using PubMed and Embase databases. Risk ratio (RR), hazard ratio (HR), and 95% confidence interval (CI) were used as the effect measures. All statistical analyses were performed using Stata software 12.0.ResultsOur results indicated that high plasma 25(OH)D levels were inversely associated with pancreatic cancer mortality without significant heterogeneity (HR=0.81, 95% CI=0.68–0.96). However, high plasma 25(OH)D levels could not reduce pancreatic cancer risk (RR=1.02, 95% CI=0.66–1.57). Moreover, vitamin D intake was also not associated with pancreatic cancer risk (RR=1.11, 95% CI=0.67–1.86)ConclusionsOur results indicate that high plasma 25(OH)D levels were significantly associated with improved survival in pancreatic cancer patients. However, there were no significant associations between vitamin D intake or plasma 25(OH)D levels and pancreatic cancer risk.

show abstract

Section: Resultsmentioning

confidence: 99%

Plasma 25-hydroxyvitamin D levels, vitamin D intake, and pancreatic cancer risk or mortality: a meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…After resection, reported nutritional deficiencies include fat‐soluble vitamins A, D, and E, vitamins B12 and B6, iron, zinc, selenium, biotin, and copper. None of these can be considered diagnostic of malnutrition; however, vitamin D deficiency has been reported in patients with PC and may contribute to poor outcomes . These findings were concluded from retrospective analysis, and it is not clear whether vitamin D supplementation improves outcomes.…”

Section: Assessment Of Pawlmentioning

confidence: 95%

Pancreas Cancer-Associated Weight Loss

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Based on previous studies, additional factors such as district should be taken into consideration and further assessed. For example, there might be no statistical significance between plasma 25(OH)D levels and pancreatic cancer risk in European populations, whereas high circulating vitamin D levels showed protective effect on pancreatic cancer prognosis in USA cohorts 56 , 57 .…”

Section: Potentiating Vitamin D As An Anticancer Agentmentioning

confidence: 98%

Repurposing vitamin D for treatment of human malignancies via targeting tumor microenvironment

Lü

et al. 2019

Acta Pharmaceutica Sinica B

113

View full text Add to dashboard Cite

Tumor cells along with a small proportion of cancer stem cells exist in a stromal microenvironment consisting of vasculature, cancer-associated fibroblasts, immune cells and extracellular components. Recent epidemiological and clinical studies strongly support that vitamin D supplementation is associated with reduced cancer risk and favorable prognosis. Experimental results suggest that vitamin D not only suppresses cancer cells, but also regulates tumor microenvironment to facilitate tumor repression. In this review, we have outlined the current knowledge on epidemiological studies and clinical trials of vitamin D. Notably, we summarized and discussed the anticancer action of vitamin D in cancer cells, cancer stem cells and stroma cells in tumor microenvironment, providing a better understanding of the role of vitamin D in cancer. We presently re-propose vitamin D to be a novel and economical anticancer agent.

show abstract

Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival

Abstract: We observed longer overall survival in patients with pancreatic cancer who had sufficient prediagnostic plasma levels of 25(OH)D.

Cited by 47 publications

References 41 publications

Plasma 25-hydroxyvitamin D levels, vitamin D intake, and pancreatic cancer risk or mortality: a meta-analysis

Plasma 25-hydroxyvitamin D levels, vitamin D intake, and pancreatic cancer risk or mortality: a meta-analysis

Pancreas Cancer-Associated Weight Loss

Repurposing vitamin D for treatment of human malignancies via targeting tumor microenvironment

Contact Info

Product

Resources

About